SERVICES) AGREEMENTServices) Agreement • March 1st, 2017 • Portola Pharmaceuticals Inc • Pharmaceutical preparations • New York
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.
= Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.2016 Supplemental Funding Support Loan Agreement • March 1st, 2017 • Portola Pharmaceuticals Inc • Pharmaceutical preparations • New York
This 2016 Supplemental Funding Support Loan Agreement (the “Agreement”) is entered into and made effective as of December 16, 2016 (the “Effective Date”), by and between, on the one hand, Portola Pharmaceuticals, Inc., a Delaware corporation, having an address of 270 East Grand Avenue, Suite 22, South San Francisco, CA 94080 (“Portola”), and on the other hand, Bristol-Myers Squibb Company, a Delaware corporation, having an address of 345 Park Avenue, New York, NY 10154 (“BMS”), and Pfizer Inc., a Delaware corporation, having an address of 235 East 42nd Street, New York, NY 10017 (“Pfizer”). Each of Portola, BMS and Pfizer are referred to individually as a “Party” and collectively as the “Parties”.
